FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975807698> ?p ?o ?g. }

• W1975807698 endingPage "1128" @default.
• W1975807698 startingPage "1123" @default.
• W1975807698 abstract "Papillary renal cell carcinoma (PRCC), type 1 and type 2, represents 10%-15% of renal cell carcinomas (RCC). There is no standard first-line treatment of metastatic PRCC (mPRCC). Anti-angiogenics have shown activity in retrospective studies but no prospective studies in pure papillary histology have been reported, but one with foretinib.A prospective phase II study evaluated sunitinib in first-line treatment of mPRCC. The primary end point was overall response rate (ORR). Secondary end points were progression-free survival (PFS) and overall survival (OS).Fifteen and 46 patients, respectively, with type 1 and type 2 mPRCC were enrolled. Using the MSKCC scoring system: 12 (20%), 33 (55%) and 9 (15%) patients were, respectively, in the favourable, intermediate or poor risk group and 7 undetermined. Median follow-up is 51.4 months. In type 1, 2 patients 13% [95% confidence interval (CI) 0.1-30.5] had a partial response (PR), 10 had stable disease (SD) with 5 (33%) ≥12 weeks. In type 2, 5 patients 11% (95% CI 1.9-20.3) had a PR, 25 had SD with 10(22%) ≥12 weeks. Median PFS was 6.6 months (95% CI 2.8-14.8) in type 1 and 5.5 months (95% CI 3.8-7.1) in type 2. Median OS was 17.8 (95% CI 5.7-26.1) and 12.4 (95% CI 8.2-14.3) months, respectively, in type 1 and 2. Safety was as expected with sunitinib for metastatic RCC.Sunitinib showed activity in treatment of type 1 and 2 mPRCC but lower than in clear-cell mRCC. Both PFS and OS are longer in type I PRCC. Sunitinib represents an acceptable option in first-line treatment of mPRCC." @default.
• W1975807698 created "2016-06-24" @default.
• W1975807698 creator A5021549650 @default.
• W1975807698 creator A5028644413 @default.
• W1975807698 creator A5033220136 @default.
• W1975807698 creator A5040479101 @default.
• W1975807698 creator A5040832651 @default.
• W1975807698 creator A5043616693 @default.
• W1975807698 creator A5047019507 @default.
• W1975807698 creator A5049672639 @default.
• W1975807698 creator A5055203198 @default.
• W1975807698 creator A5062822105 @default.
• W1975807698 creator A5067036952 @default.
• W1975807698 creator A5069166380 @default.
• W1975807698 creator A5076243488 @default.
• W1975807698 creator A5076354847 @default.
• W1975807698 date "2015-06-01" @default.
• W1975807698 modified "2023-10-09" @default.
• W1975807698 title "First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)" @default.
• W1975807698 cites W1544119899 @default.
• W1975807698 cites W1965046203 @default.
• W1975807698 cites W2013321025 @default.
• W1975807698 cites W2068521555 @default.
• W1975807698 cites W2074416418 @default.
• W1975807698 cites W2081372483 @default.
• W1975807698 cites W2100669312 @default.
• W1975807698 cites W2116095691 @default.
• W1975807698 cites W2119888873 @default.
• W1975807698 cites W2123626002 @default.
• W1975807698 cites W2139248078 @default.
• W1975807698 cites W2141444851 @default.
• W1975807698 cites W2143813821 @default.
• W1975807698 cites W2149456801 @default.
• W1975807698 cites W2150954721 @default.
• W1975807698 cites W2153867442 @default.
• W1975807698 cites W2155771281 @default.
• W1975807698 cites W2160120519 @default.
• W1975807698 cites W2161130083 @default.
• W1975807698 cites W2161797239 @default.
• W1975807698 cites W2162225483 @default.
• W1975807698 cites W2162424705 @default.
• W1975807698 cites W2168622014 @default.
• W1975807698 cites W2314279698 @default.
• W1975807698 cites W2337061424 @default.
• W1975807698 cites W3010644992 @default.
• W1975807698 cites W4251738294 @default.
• W1975807698 doi "https://doi.org/10.1093/annonc/mdv149" @default.
• W1975807698 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25802238" @default.
• W1975807698 hasPublicationYear "2015" @default.
• W1975807698 type Work @default.
• W1975807698 sameAs 1975807698 @default.
• W1975807698 citedByCount "110" @default.
• W1975807698 countsByYear W19758076982015 @default.
• W1975807698 countsByYear W19758076982016 @default.
• W1975807698 countsByYear W19758076982017 @default.
• W1975807698 countsByYear W19758076982018 @default.
• W1975807698 countsByYear W19758076982019 @default.
• W1975807698 countsByYear W19758076982020 @default.
• W1975807698 countsByYear W19758076982021 @default.
• W1975807698 countsByYear W19758076982022 @default.
• W1975807698 countsByYear W19758076982023 @default.
• W1975807698 crossrefType "journal-article" @default.
• W1975807698 hasAuthorship W1975807698A5021549650 @default.
• W1975807698 hasAuthorship W1975807698A5028644413 @default.
• W1975807698 hasAuthorship W1975807698A5033220136 @default.
• W1975807698 hasAuthorship W1975807698A5040479101 @default.
• W1975807698 hasAuthorship W1975807698A5040832651 @default.
• W1975807698 hasAuthorship W1975807698A5043616693 @default.
• W1975807698 hasAuthorship W1975807698A5047019507 @default.
• W1975807698 hasAuthorship W1975807698A5049672639 @default.
• W1975807698 hasAuthorship W1975807698A5055203198 @default.
• W1975807698 hasAuthorship W1975807698A5062822105 @default.
• W1975807698 hasAuthorship W1975807698A5067036952 @default.
• W1975807698 hasAuthorship W1975807698A5069166380 @default.
• W1975807698 hasAuthorship W1975807698A5076243488 @default.
• W1975807698 hasAuthorship W1975807698A5076354847 @default.
• W1975807698 hasBestOaLocation W19758076981 @default.
• W1975807698 hasConcept C126322002 @default.
• W1975807698 hasConcept C126894567 @default.
• W1975807698 hasConcept C141071460 @default.
• W1975807698 hasConcept C143998085 @default.
• W1975807698 hasConcept C168563851 @default.
• W1975807698 hasConcept C203092338 @default.
• W1975807698 hasConcept C2776694085 @default.
• W1975807698 hasConcept C2777472916 @default.
• W1975807698 hasConcept C2779490328 @default.
• W1975807698 hasConcept C31760486 @default.
• W1975807698 hasConcept C71924100 @default.
• W1975807698 hasConcept C90924648 @default.
• W1975807698 hasConceptScore W1975807698C126322002 @default.
• W1975807698 hasConceptScore W1975807698C126894567 @default.
• W1975807698 hasConceptScore W1975807698C141071460 @default.
• W1975807698 hasConceptScore W1975807698C143998085 @default.
• W1975807698 hasConceptScore W1975807698C168563851 @default.
• W1975807698 hasConceptScore W1975807698C203092338 @default.
• W1975807698 hasConceptScore W1975807698C2776694085 @default.
• W1975807698 hasConceptScore W1975807698C2777472916 @default.
• W1975807698 hasConceptScore W1975807698C2779490328 @default.

• next